Sign in to continue:

Friday, February 20th, 2026
us corporate news

Artiva Biotherapeutics, Inc. 8-K Filing: Company Information, Address, and SEC Details (2026)

Posted on February 20, 2026 at 5:38 pm (GMT+8)

11
Views
Share on Facebook
Share on Twitter

NIL
Disclaimer:
This article is for informational purposes only and does not constitute investment advice. Readers are encouraged to conduct their own research and consult with their financial advisor before making any investment decisions.

View Artiva Biotherapeutics, Inc. Historical chart here



Related Posts

us corporate news

Shutterstock Issues Statement on UK CMA’s Provisional Findings Regarding Getty Images Merger – 8-K SEC Filing Summary
minichart
February 20, 2026

Shutterstock Issues Statement on CMA Interim Report Regarding Getty Images Merger Shutterstock Issues Statement on UK CMA’s Provisional Findings Regarding Proposed Merger with Getty Images Key Developments in a Market-Shaping Deal February 19, 2026...

us corporate news

Marsh & McLennan Companies, Inc. 8-K Filing: $600 Million 4.950% Senior Notes Due 2036, Entity Information, and XBRL Data
minichart
February 20, 2026

Marsh & McLennan Companies Announces \$600 Million Senior Notes Offering New York, February 19, 2026 – Marsh & McLennan Companies, Inc. (“MMC”), a global professional services firm, has announced the successful pricing and execution...

us corporate news

Copart, Inc. Reports Q2 Fiscal 2026 Financial Results: Revenue and Profit Decline, Strong Cash Flow and Global Operations 1
minichart
February 20, 2026

Copart, Inc. Q2 2026 Financial Results: Key Insights for Investors Copart, Inc. Reports Q2 2026 Financial Results: Revenue Declines, Net Income Falls, Cash Surges Key Highlights Revenue: \$1.1 billion for the quarter ended January...

   Ad